MedAll

We're on a mission to make great medical education accessible, to every healthcare professional. MedAll is an EBAC accredited provider.

[MedAll @MedAllApp]

👋Calling all HCPs.

We’re exploring generalized myasthenia gravis in Europe.

Is the following a gap in clinical practice?

Limited practical guidance to support HCPs in integrating an expanding, mechanistically diverse treatment landscape into everyday decision-making.

[MedAll @MedAllApp]

‼️HCPs, we want your opinion.

We’re exploring generalized myasthenia gravis in Europe.

Is the following a gap in clinical practice?

HCPs underuse standardized patient outcomes measures and underestimate the disease burden for patients

[MedAll @MedAllApp]

📢Clinician insights wanted

We’re exploring generalized myasthenia gravis in Europe.

Is the following a gap in clinical practice?

HCPs rely on conventional immunosuppression, and delay the use of targeted, mechanism-based therapies

[MedAll @MedAllApp]

🥼 Calling all HCPs, we’d love your input on care for people with isolated REM sleep behavior disorder.

Is this a gap in clinical practice?

Discussing future neurodegenerative risk and uncertainty while incorporating individual patient preferences.

[MedAll @MedAllApp]

Welcome to the next instalment in our accredited Epithelioid Sarcoma Quick Bits social learning series.

Watch this short reel with Dr Seth Pollack on the role of INI1 loss in diagnosing epithelioid sarcoma.

Review evidence-based diagnostic considerations, including:
🔬 INI1 loss as a key clue in suspected ES
🧫 Morphology and broad immunohistochemistry in the differential diagnosis
🧬 When SMARCB1 FISH or NGS may support confirmation
🤝 Integrating pathology, imaging, and multidisciplinary review

Please read the CE information and disclosures here before participating in this activity:
https://t.co/qtCztWi4CK

This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally.

👉🏽 Get the full series in the link below

https://t.co/aJBAtgbKau

[MedAll @MedAllApp]

This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below.

Watch this short reel with Dr Hannah Abrams on treatment sequencing beyond first-line therapy in epithelioid sarcoma.

Review evidence-based considerations for later-line ES management, including:
🔄 Sequencing options after progression on first-line therapy
💊 Anthracycline-, gemcitabine-, and pazopanib-based approaches
📊 Real-world response and progression-free survival data
🤝 Individualizing treatment based on subtype, tolerability, quality of life, and patient goals
🏥 Referral to sarcoma-specialized centers and clinical trial consideration

Please read the CE information and disclosures here before participating in this activity:
https://t.co/qtCztWi4CK

This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally.

👉🏽 Get the full series in the link below

https://t.co/aJBAtgbKau

[MedAll @MedAllApp]

Check out the next part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below.

Watch this short reel with Dr Hannah Abrams on emerging treatment directions in epithelioid sarcoma.

Review evidence-based considerations on evolving approaches, including:
🧬 SMARCB1-deficient biology and rationale for targeted strategies
💊 Anti-angiogenic TKI-based combinations in soft-tissue sarcoma
🛡️ Immunotherapy combinations, including checkpoint blockade approaches
📊 Emerging clinical data and investigational strategies relevant to ES
🏥 Clinical trial consideration in this ultra-rare sarcoma

Please read the CE information and disclosures here before participating in this activity:
https://t.co/qtCztWi4CK

This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally.

👉🏽 Get the full series in the link below

https://t.co/aJBAtgbKau

[MedAll @MedAllApp]

This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below.

Watch this short reel with Dr Hannah Abrams on first-line systemic therapy considerations in advanced epithelioid sarcoma.

Review evidence-based treatment considerations, including:
💊 Anthracycline-based chemotherapy as a preferred first-line systemic approach
🧬 Classic vs proximal-type ES and implications for treatment discussions
📊 Real-world data on doxorubicin- and gemcitabine-based regimens
🤝 Individualizing therapy based on disease extent, comorbidities, performance status, and patient goals

Please read the CE information and disclosures here before participating in this activity:
https://t.co/qtCztWi4CK

This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally.

👉🏽 Get the full series in the link below

[MedAll @MedAllApp]

Welcome to our new, accredited social learning series on Epithelioid Sarcoma: Quick Bits.

Watch this short reel with Dr Seth Pollack on early recognition of epithelioid sarcoma.

Review evidence-based warning signs that may prompt further evaluation, including:
🔎 Slow-growing, painless soft-tissue nodules
📏 Size, depth, pain, firmness, or progressive enlargement
🩻 MRI features that may raise suspicion
🤝 When to escalate to biopsy and multidisciplinary review

Please read the CE information and disclosures here before participating in this activity:
https://t.co/qtCztWi4CK

This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally.

👉🏽 Get the full series in the link below

[MedAll @MedAllApp]

👋HCPs, we'd value your perspective

We're exploring understanding of IgAN pathogenesis.

Is the following a gap in clinical practice?

Understanding the role of B-cell dysregulation and upstream immune mechanisms in the progression of IgAN:

[MedAll @MedAllApp]

📣Calling all HCPs

We’re exploring alcohol-use disorder (AUD) management

Is the following a gap in clinical practice?

HCPs face challenges in routinely employing screening tools to proactively identify mild-to-moderate AUD

[MedAll @MedAllApp]

🩺Quick question for HCPs

We’re exploring IBD care

Is the following a gap in clinical practice?

HCPs face challenges applying STRIDE-II treat-to-target recommendations in real-world IBD care

[MedAll @MedAllApp]

🤝 Calling all healthcare professionals involved in platinum-resistant ovarian cancer care. We'd love your input.

How challenging is coordinating multidisciplinary ADC care, patient education, and supportive care for patients receiving treatment?

[MedAll @MedAllApp]

🏥 Calling all healthcare professionals involved in platinum-resistant ovarian cancer care. We'd love your input.

How challenging is implementing coordinated ADC care pathways, including infusion readiness, workflow coordination, and care transitions?

[MedAll @MedAllApp]

💊 Calling all healthcare professionals involved in platinum-resistant ovarian cancer care. We'd love your input.

How challenging is managing ADC-related toxicities while making treatment continuation and dose-modification decisions?

[MedAll @MedAllApp]

⁉️Quick question for clinicians

We are exploring advances in the treatment of TNBC

Is the following a gap in clinical practice?

HCPs have low confidence selecting patients for and integrating novel immunomodulators into TNBC treatment pathways.

[MedAll @MedAllApp]

If you attended our recent live session, please take a moment to share your feedback with us. How confident are you in applying an understanding of cardiorenal pathophysiology to lead a multidisciplinary, team-based approach for managing patients with T2D and CKD?